Kenya Researchers Confident Population Will Embrace Malaria Vaccine

肯亞研究員對於全民施打瘧疾疫苗樂觀其成

More than 260,000 African children under the age of five die from malaria each year, including more than 10,000 in Kenya, according to the World Health Organization. The WHO's backing of a malaria vaccine, Mosquirix, for children in sub-Saharan Africa has raised hopes of preventing those deaths. The vaccine proved effective in a pilot program in Ghana, Kenya, and Malawi.

根據世界衛生組織，每天有超過 26 萬名五歲以下的非洲孩童死於瘧疾，其中更有超過 1 萬名是在肯亞，一款由世界衛生組織支援的瘧疾疫苗 Mosquirix 已為撒哈拉非洲的孩童帶來一線曙光，在肯亞、迦納和馬拉威先行試用後證實其有效性。

英語聽力大翻轉：6技巧突破英聽困境                                                                                  

您是否也有以下困擾：
「雖然常開著英文廣播，還是聽不懂……」
「聽英語時，聽到後面常常就忘了前面講了什麼……」
「不知從何時就開始神遊，注意力不再集中……」
來看看這本書就,可以找到解決妙方！

Kenya Researchers Confident Population Will Embrace Malaria Vaccine
VOA News｜Africa
October 07, 2021 12:25 PM (source)

Kenya Researchers Confident Population Will Embrace Malaria Vaccine

肯亞研究員對於全民施打瘧疾疫苗樂觀其成

October 07, 2021 12:25 PM

NAIROBI

  VOA News 搶先看 

非洲有超過 25 萬名孩童死於蚊蟲傳染，世界衛生組織（WHO）週三（按編：10 月 6 日）宣布，批准瘧疾疫苗 Mosquirix，這無疑是對抗致命傳染病的一大救星。WHO 秘書長譚德塞（Tedros Ghebreyesus）對此表示，這款疫苗是歷史性的突破，每年可以挽救數以萬計的年幼生命。肯亞經過大規模的試驗後，研究機構有信心可進行廣泛施打，保護更多孩童，使他們健康成長。

More than 260,000 African children under the age of five die from malaria each year, including more than 10,000 in Kenya, according to the World Health Organization. The WHO's backing of a malaria vaccine, Mosquirix, for children in sub-Saharan Africa has raised hopes of preventing those deaths. The vaccine proved effective in a pilot program in Ghana, Kenya, and Malawi.

On Wednesday, the World Health Organization gave the green light for the use of the vaccine for children between five and 24 months of age in Africa and other regions prone to a high level of malaria transmission.

This follows trials of the vaccine in Ghana, Kenya and Malawi. The four-dose shot was administered to 800,000 African children.

Thirty-year-old Salome Awuor allowed her son, now three years old, to take part in the malaria vaccine trials in Kisumu County, western Kenya.

The mother of four said previously she would visit her nearest clinic four times a month to get malaria treatment for him. At the time, he was 12 months old.

"My son was given three jabs, and malaria went down. I never went back to the clinic seeking malaria treatment. I feel so good my children no longer get sick most of the time. That's why whenever I hear about vaccines, I run to get them because it helps a lot," she said.

WHO chief Tedros Ghebreyesus described the malaria vaccine breakthrough as historic and one that could save the lives of tens of thousands of young people each year.

According to the WHO, malaria affects more than 229 million people each year and kills more than 400,000.

In Africa, more than a quarter of a million children die from the mosquito-borne disease.

Earlier trials in 2015 showed the vaccine could prevent 40 percent of malaria cases and about 30 percent of severe cases.

Bernhards Ogutu is a chief researcher at Kenya Medical Research Institute. He said Kenya's participation in the study proves the vaccine will work on the country's population.

"If it's safe you know it was done in your population and you know it's good for you. You are not relying on data from another population but from your own population. So that you can confidently advise the government this is safe for us, it works and its approved and it was done by us and we contributed to this development," he said.

The first three vaccine doses are given a month apart when children are babies, and a final booster is given when the child is one-and-a-half years old.

Ogutu has voiced confidence that Kenyan parents will vaccinate their children from malaria.

"People have been asking where it is now that we have been given the go ahead, we can now go for the rollout. I think it's time to get to our people and tell them now it's available and now it's a matter of procuring the vaccine and ensuring it's available and start getting it to those who need it," said Ogutu.

So far, there is no word on when the vaccine will become available to the general public.